专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

US20120101260A1 SUSTAINED DRUG DELIVERY SYSTEM 有权
标题翻译：持续的药物输送系统
公开(公告)号：US20120101260A1
公开(公告)日：2012-04-26
申请号：US13088354
申请日：2011-04-16
申请人： Kathleen Cogan Farinas , Steven Chamow
发明人： Kathleen Cogan Farinas , Steven Chamow
IPC分类号： C07K17/10 , C12P21/02 , C07K16/46
CPC分类号： A61K47/645 , A61K47/61
摘要： A drug composition comprising a charged moiety coupled to a therapeutic compound is disclosed. The charged moiety is configured to interact with at least one type of component of opposite charge in a biological tissue to create an in situ depot for prolonged drug delivery. The biological tissue may be eye tissue or any tissue containing charged components.
摘要翻译：公开了包含与治疗化合物偶联的带电部分的药物组合物。带电部分被配置为与生物组织中的相反电荷的至少一种类型的组分相互作用以产生用于延长药物递送的原位贮库。生物组织可以是眼组织或含有带电组分的任何组织。

2. 发明授权

US5849689A Method of extending the plasma half-life of deletion variants of hepatocyte growth factor 失效
标题翻译：延长肝细胞生长因子缺失变体血浆半衰期的方法
公开(公告)号：US5849689A
公开(公告)日：1998-12-15
申请号：US466326
申请日：1995-06-06
申请人： Steven Chamow , Nishit Modi , Ralph Schwall , Thomas Zioncheck
发明人： Steven Chamow , Nishit Modi , Ralph Schwall , Thomas Zioncheck
IPC分类号： A61K38/22 , A61K9/00 , A61K31/715 , A61K38/17 , A61K38/18 , A61K47/36 , A61P1/16
CPC分类号： A61K9/0019 , A61K31/721 , A61K31/727 , A61K38/178 , A61K45/06 , A61K47/36
摘要： The invention provides a method for extending the plasma half-life of heparin-binding proteins by coadministering such proteins with a therapeutically acceptable compound capable of inhibiting their binding to a low affinity heparin-like binding site on the surface of the cells. In one embodiment of the invention, the heparin-binding protein is a growth factor. The binding inhibitory compound can, for example, be a purified native heparin preparation, a heparin fragment, or another polyanionic compound, such as dextran sulfate, heparan sulfate, pentosan sulfate, or hyaluronate.
摘要翻译：本发明提供了一种延长肝素结合蛋白的血浆半衰期的方法，其通过用能够抑制它们与细胞表面上的低亲和力肝素结合位点的结合的治疗上可接受的化合物共同掺入这种蛋白质。在本发明的一个实施方案中，肝素结合蛋白是生长因子。结合抑制性化合物可以是例如纯化的天然肝素制剂，肝素片段或另一种聚阴离子化合物，例如硫酸葡聚糖，硫酸乙酰肝素，戊糖硫酸盐或透明质酸盐。

3. 发明授权

US08535681B2 Sustained drug delivery system 有权
标题翻译：持续的药物输送系统
公开(公告)号：US08535681B2
公开(公告)日：2013-09-17
申请号：US13124654
申请日：2009-10-15
申请人： Kathleen Cogan Farinas , Steven Chamow
发明人： Kathleen Cogan Farinas , Steven Chamow
IPC分类号： A61K39/00 , A61K39/44 , A61K39/395 , A61K38/10 , A61K38/08 , C07K19/00 , C07K16/22 , C07K4/12 , C07K14/00
CPC分类号： A61K9/0048 , A61K47/645
摘要： A drug composition comprising a charged moiety coupled to a therapeutic compound is disclosed. The charged moiety is configured to interact with at least one type of component of opposite charge in a biological tissue to create an in situ depot for prolonged drug delivery. The biological tissue may be eye tissue or any tissue containing charged components. Further, a method of treating the human body is disclosed. The method is for introducing into a human body a drug composition comprising a charged moiety coupled to a therapeutic compound. Introduction may be through injection. A method of manufacturing a drug composition comprising a charged moiety coupled to a therapeutic compound is also disclosed.
摘要翻译：公开了包含与治疗化合物偶联的带电部分的药物组合物。带电部分被配置为与生物组织中的相反电荷的至少一种类型的组分相互作用以产生用于延长药物递送的原位贮库。生物组织可以是眼组织或含有带电组分的任何组织。此外，公开了一种治疗人体的方法。该方法用于向人体引入包含与治疗化合物偶联的带电部分的药物组合物。介绍可能是通过注射。还公开了包含与治疗化合物偶联的带电部分的药物组合物的制造方法。

4. 发明申请

US20110200599A1 SUSTAINED DRUG DELIVERY SYSTEM 有权
标题翻译：持续的药物输送系统
公开(公告)号：US20110200599A1
公开(公告)日：2011-08-18
申请号：US13124654
申请日：2009-10-15
申请人： Kathleen Cogan Farinas , Steven Chamow
发明人： Kathleen Cogan Farinas , Steven Chamow
IPC分类号： A61K39/395 , A61P27/02 , A61P35/00
CPC分类号： A61K9/0048 , A61K47/645
摘要： A drug composition comprising a charged moiety coupled to a therapeutic compound is disclosed. The charged moiety is configured to interact with at least one type of component of opposite charge in a biological tissue to create an in situ depot for prolonged drug delivery. The biological tissue may be eye tissue or any tissue containing charged components. Further, a method of treating the human body is disclosed. The method is for introducing into a human body a drug composition comprising a charged moiety coupled to a therapeutic compound. Introduction may be through injection. A method of manufacturing a drug composition comprising a charged moiety coupled to a therapeutic compound is also disclosed.
摘要翻译：公开了包含与治疗化合物偶联的带电部分的药物组合物。带电部分被配置为与生物组织中的相反电荷的至少一种类型的组分相互作用以产生用于延长药物递送的原位贮库。生物组织可以是眼组织或含有带电组分的任何组织。此外，公开了一种治疗人体的方法。该方法用于向人体引入包含与治疗化合物偶联的带电部分的药物组合物。介绍可能是通过注射。还公开了包含与治疗化合物偶联的带电部分的药物组合物的制造方法。

5. 发明授权

US5464815A Inhibition of heparin-binding 失效
标题翻译：抑制肝素结合
公开(公告)号：US5464815A
公开(公告)日：1995-11-07
申请号：US254390
申请日：1994-06-06
申请人： Steven Chamow , Nishit Modi , Ralph Schwall , Thomas Zioncheck
发明人： Steven Chamow , Nishit Modi , Ralph Schwall , Thomas Zioncheck
IPC分类号： A61K38/22 , A61K9/00 , A61K31/715 , A61K38/17 , A61K38/18 , A61K47/36 , A61P1/16 , C07K1/14 , G01N33/68
CPC分类号： A61K9/0019 , A61K31/721 , A61K31/727 , A61K38/178 , A61K45/06 , A61K47/36
摘要： The invention provides a method for extending the plasma half-life of heparin-binding proteins by coadministering such proteins with a therapeutically acceptable compound capable of inhibiting their binding to a low affinity heparin-like binding site on the surface of cells. In one embodiment of the invention, the-heparin-binding protein is a selectin. The binding inhibitory compound can, for example, be a purified native heparin preparation, a heparin fragment, or another polyanionic compound, such as dextran sulfate, heparan sulfate, pentosan sulfate, or hyaluronate.
摘要翻译：本发明提供了一种延长肝素结合蛋白的血浆半衰期的方法，其通过用能够抑制它们与细胞表面上的低亲和力肝素结合位点的结合的治疗上可接受的化合物共同掺入这种蛋白质。在本发明的一个实施方案中，肝素结合蛋白是选择蛋白。结合抑制化合物可以是例如纯化的天然肝素制剂，肝素片段或另一种聚阴离子化合物，例如硫酸葡聚糖，硫酸乙酰肝素，戊糖硫酸酯或透明质酸盐。

6. 发明授权

US5851989A Method of extending the plasma half-life of vascular endothelial cell growth factor 失效
标题翻译：延长血管内皮细胞生长因子血浆半衰期的方法
公开(公告)号：US5851989A
公开(公告)日：1998-12-22
申请号：US465895
申请日：1995-06-06
申请人： Steven Chamow , Nishit Modi , Ralph Schwall , Thomas Zioncheck
发明人： Steven Chamow , Nishit Modi , Ralph Schwall , Thomas Zioncheck
IPC分类号： A61K38/22 , A61K9/00 , A61K31/715 , A61K38/17 , A61K38/18 , A61K47/36 , A61P1/16
CPC分类号： A61K9/0019 , A61K31/721 , A61K31/727 , A61K38/178 , A61K45/06 , A61K47/36
摘要： The invention provides a method for extending the plasma half-life of heparin-binding proteins by coadministering such proteins with a therapeutically acceptable compound capable of inhibiting their binding to a low affinity heparin-like binding site on the surface of cells. In one embodiment of the invention, the heparin-binding protein is a growth factor or selectin. The binding inhibitory compound can, for example, be a purified native heparin preparation, a heparin fragment, or another polyanionic compound, such as dextran sulfate, heparan sulfate, pentosan sulfate, or hyaluronate.
摘要翻译：本发明提供了一种延长肝素结合蛋白的血浆半衰期的方法，其通过用能够抑制它们与细胞表面上的低亲和力肝素结合位点的结合的治疗上可接受的化合物共同掺入这种蛋白质。在本发明的一个实施方案中，肝素结合蛋白是生长因子或选择蛋白。结合抑制性化合物可以是例如纯化的天然肝素制剂，肝素片段或另一种聚阴离子化合物，例如硫酸葡聚糖，硫酸乙酰肝素，戊糖硫酸盐或透明质酸盐。

7. 发明授权

US08530189B2 Sustained drug delivery system 有权
标题翻译：持续的药物输送系统
公开(公告)号：US08530189B2
公开(公告)日：2013-09-10
申请号：US13088354
申请日：2011-04-16
申请人： Kathleen Cogan Farinas , Steven Chamow
发明人： Kathleen Cogan Farinas , Steven Chamow
IPC分类号： C07K19/00 , C07K4/12 , C07K14/00 , C07K16/22 , C12P21/02 , A61K39/00 , A61K38/10
CPC分类号： A61K47/645 , A61K47/61
摘要： A drug composition comprising a charged moiety coupled to a therapeutic compound is disclosed. The charged moiety is configured to interact with at least one type of component of opposite charge in a biological tissue to create an in situ depot for prolonged drug delivery. The biological tissue may be eye tissue or any tissue containing charged components.
摘要翻译：公开了包含与治疗化合物偶联的带电部分的药物组合物。带电部分被配置为与生物组织中的相反电荷的至少一种类型的组分相互作用以产生用于延长药物递送的原位贮库。生物组织可以是眼组织或含有带电组分的任何组织。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式